Data Sheet (Cat.No.T13295)

TargetMol

Veliflapon

Chemical Properties



CAS No. : 128253-31-6

Formula: C23H23NO3

Molecular Weight: 361.43

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Veliflapon is an orally active and selective inhibitor of 5-lipoxygenase activating protein (FLAP). Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
Targets(IC50)	LTR
In vitro	Veliflapon inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice and humans with IC50s of 0.026, 0.039 and 0.22 μM, respectively as well as the formation of LTC4 with IC50 of 0.021 μM in mouse peritoneal macrophages stimulated with opsonized zymosan[3].
In vivo	Atherogenesis inhibited by Veliflapon (DG-031; diet; 18.8 mg/kg/day for 16 weeks). In the arachidonic acid-induced mouse ear inflammation test,Veliflapon after topical (18 μg/ear) and oral (48.7 mg/kg) administration has antiedematous effects [4]. Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED40 of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay[4].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7668 mL	13.8339 mL	27.6679 mL
5 mM	0.5534 mL	2.7668 mL	5.5336 mL
10 mM	0.2767 mL	1.3834 mL	2.7668 mL
50 mM	0.0553 mL	0.2767 mL	0.5534 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43(1-2):64-8.
Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7.
Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.
Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481